GRAIL and Fountain health insurance partner to cover Galleri® early cancer test

MENLO PARK, California, and Naples, Florida – (BUSINESS CHP) – GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Fountain Health Insurance (Fountain Health) today announced a partnership to offer Galleri®blood test for early detection of many cancers (MCED) of GRAIL, to Fountain Health customers at 100% coverage as part of its annual health benefits.

“Our partnership with GRAIL is a great opportunity to change the health history of thousands of people by detecting cancer at an early stage so that we can improve our results. However, saving the life of an employee or loved one is what will really make this transformative. What better gift could you give your employees? ”Said Robert J. Rossiter, CEO of Fountain Health.

The Galleri test is the first MCED blood test of its kind. In a clinical trial, the Galleri test demonstrated the ability to detect a shared signal from more than 50 cancers, more than 45 of which do not have recommended screening tests today. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide diagnostic processing. Early detection of cancer has been shown to improve cancer outcomes, but today most cancers are detected in the late stages, as only five cancers have been recommended for screening – breast, cervical, colon, white liver and prostate cancer.

“We commend Fountain Health for its commitment to proactive care and cancer detection earlier, when treatment is more likely to be successful, “said Bob Ragusa, CEO of GRAIL. “By offering the Galleri test and covering it 100%, Fountain Health helps ensure that more people have access to critical health information that could give them a better chance of surviving cancer, which still takes more lives. of 600,000 people a year in the United States.

For Fountain Health Insurance

Fountain Health believes that employees are the company’s most important asset. Investing in employee health encourages employees to invest back in the company. Fountain Health provides the highest standard of coverage for large group health insurance. However, the main focus of Fountain Health is on proactive care and maintaining people’s health: not only does preventive health save lives by preventing the disease or catching it early while it is still highly treatable – it saves money. Early detection costs a small part of the detection and treatment of diseases such as cancer, heart disease and diabetes in their more advanced stages. Fountain Health can change lives by transforming insurance. Fountain Health is headquartered in Naples, Florida, with a service location in Wilmington, North Carolina. A new global headquarters has been announced, which will soon be opened in Lake Nona, Florida. Learn more at www.fountainhealth.com.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured. GRAIL is focused on alleviating the global cancer burden by developing pioneering technology for the early detection and identification of many deadly cancers. The company is using the power of next-generation sequencing, population-based clinical trials and state-of-the-art computer science and data science to improve scientific understanding of cancer biology and develop its blood for early detection of many cancers. test. GRAIL is headquartered in Menlo Park, California with locations in Washington, DC, North Carolina and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN), currently held separately from Illumina Inc. under the terms of the European Commission’s Interim Measure Order of 29 October 2021

For more information, please visit grail.com.

About Galleries®

The earlier the cancer is detected, the greater the chance of successful results. Galleri’s Early Detection Test for Multiple Cancers can detect a shared cancer signal from more than 50 cancers, as defined by the US Joint Committee on the Staging of Cancer, through routine blood sampling. When a cancer signal is detected, the Galleri test predicts the origin of the cancer signal or where the cancer is located in the body with high accuracy to help guide the next steps toward diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer tests such as mammography, colonoscopy, prostate specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people at increased risk of cancer, such as those aged 50 or over.

For more information on Galleri, visit galleri.com.

Important gallery safety information

The Galleri test is recommended for use in adults at increased risk of cancer, such as those aged 50 years or older. The Galleri test does not detect all types of cancer and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is designed to detect cancer signals and predict where the cancer signal is located in the body. Galleri is not recommended for use in pregnant women, 21 years of age or younger or undergoing active cancer treatment.

The results should be interpreted by the healthcare provider in the context of medical history, clinical signs and symptoms. The result of the “Cancer signal not detected” test does not rule out cancer. The result of the “Cancer Signal Test” test requires a confirmatory diagnostic evaluation through medically established procedures (eg imaging) to confirm cancer.

If the cancer is not confirmed by further testing, it may mean that the cancer is not present or the test is insufficient to detect cancer, including due to the location of the cancer in a different part of the body. False-positive (cancer signal detected when cancer is not present) and false-negative (cancer signal that is not detected when cancer is present) test results are obtained. Only Rx.

Laboratory / test information

The GRAIL Clinical Laboratory is certified under the 1988 Clinical Laboratory Amendments (CLIA) and is accredited by the College of American Pathologists. The Galleri test has been developed and its performance characteristics have been determined by GRAIL. The Galleri test is not approved or approved by the US Food and Drug Administration. The GRAIL Clinical Laboratory is regulated by the CLIA to perform highly complex tests. The Galleri test is intended for clinical purposes.

Leave a Comment

Your email address will not be published.